| Year |
Citation |
Score |
| 2020 |
Guan Y, Chambers CB, Tabatabai T, Hatley H, Delfino KR, Robinson K, Alanee SR, Ran S, Torry DS, Wilber A. Renal cell tumors convert natural killer cells to a proangiogenic phenotype. Oncotarget. 11: 2571-2585. PMID 32655841 DOI: 10.18632/Oncotarget.27654 |
0.464 |
|
| 2020 |
Sharma G, Jagtap JM, Parchur AK, Gogineni VR, Ran S, Bergom C, White SB, Flister MJ, Joshi A. Heritable modifiers of the tumor microenvironment influence nanoparticle uptake, distribution and response to photothermal therapy. Theranostics. 10: 5368-5383. PMID 32373218 DOI: 10.7150/Thno.41171 |
0.687 |
|
| 2020 |
Ran S, Volk-Draper L. Lymphatic Endothelial Cell Progenitors in the Tumor Microenvironment. Advances in Experimental Medicine and Biology. 1234: 87-105. PMID 32040857 DOI: 10.1007/978-3-030-37184-5_7 |
0.513 |
|
| 2020 |
Volk-Draper L, Patel R, Bhattarai N, Yang J, Ran S. Abstract A79: Myeloid-lymphatic endothelial progenitors significantly contribute to lymph node metastasis in clinical breast cancer Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-A79 |
0.503 |
|
| 2019 |
Volk-Draper L, Patel R, Bhattarai N, Yang J, Wilber A, DeNardo D, Ran S. Myeloid-Derived Lymphatic Endothelial Cell Progenitors Significantly Contribute to Lymphatic Metastasis in Clinical Breast Cancer. The American Journal of Pathology. PMID 31421071 DOI: 10.1016/J.Ajpath.2019.07.006 |
0.529 |
|
| 2019 |
Plasterer C, Tsaih SW, Peck AR, Chervoneva I, O'Meara C, Sun Y, Lemke A, Murphy D, Smith J, Ran S, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Mitchell EP, et al. Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome. Breast Cancer Research and Treatment. PMID 31165373 DOI: 10.1007/S10549-019-05307-8 |
0.65 |
|
| 2019 |
Holland BC, Sood A, Delfino K, Dynda DI, Ran S, Freed N, Alanee S. Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy. Cancer Immunology, Immunotherapy : Cii. PMID 30997535 DOI: 10.1007/S00262-019-02340-W |
0.309 |
|
| 2019 |
Volk-Draper LD, Ran S. Abstract 1967: Nab-paclitaxel chemotherapy of breast tumors upregulates chemokines that increase chemotaxis of myeloid-lymphatic progenitors Cancer Research. 79: 1967-1967. DOI: 10.1158/1538-7445.Sabcs18-1967 |
0.587 |
|
| 2019 |
Volk-Draper LD, Patel R, Bhattarai N, Yang J, Ran S. Abstract 1506: Lymph node metastasis in clinical breast cancer is significantly promoted by myeloid-derived lymphatic endothelial cell progenitors Immunology. DOI: 10.1158/1538-7445.Sabcs18-1506 |
0.416 |
|
| 2018 |
Datta K, Roy S, Bag AK, Dutta S, Polavaram NS, Islam R, Schellenburg S, Banwait JK, Guda C, Ran S, Hollingsworth MA, Singh RK, Talmadge JE, Muders MH, Batra SK. Macrophage-derived Neuropilin-2 exhibits novel tumor-promoting functions. Cancer Research. PMID 30111533 DOI: 10.1158/0008-5472.Can-18-0562 |
0.497 |
|
| 2017 |
Volk-Draper LD, Hall KL, Wilber AC, Ran S. Lymphatic endothelial progenitors originate from plastic myeloid cells activated by toll-like receptor-4. Plos One. 12: e0179257. PMID 28598999 DOI: 10.1371/Journal.Pone.0179257 |
0.39 |
|
| 2017 |
Flister MJ, Tsaih SW, Stoddard A, Plasterer C, Jagtap J, Parchur AK, Sharma G, Prisco AR, Lemke A, Murphy D, Al-Gizawiy M, Straza M, Ran S, Geurts AM, Dwinell MR, et al. Host genetic modifiers of nonproductive angiogenesis inhibit breast cancer. Breast Cancer Research and Treatment. PMID 28567545 DOI: 10.1007/S10549-017-4311-8 |
0.714 |
|
| 2017 |
Ran S, Wilber A. Novel role of immature myeloid cells in formation of new lymphatic vessels associated with inflammation and tumors. Journal of Leukocyte Biology. PMID 28408396 DOI: 10.1189/Jlb.1Mr1016-434Rr |
0.424 |
|
| 2016 |
Griggs C, Hall K, Volk-Draper L, Robinson K, Ran S. Abstract 1460: Bone marrow-derived CD11b + /Podoplanin + cells are lymphatic progenitors directly responsible for breast cancer lymphatic formation Cancer Research. 76: 1460-1460. DOI: 10.1158/1538-7445.Am2016-1460 |
0.574 |
|
| 2015 |
Ran S. The Role of TLR4 in Chemotherapy-Driven Metastasis. Cancer Research. 75: 2405-10. PMID 25998620 DOI: 10.1158/0008-5472.Can-14-3525 |
0.531 |
|
| 2015 |
Pimenta EM, De S, Weiss R, Feng D, Hall K, Kilic S, Bhanot G, Ganesan S, Ran S, Barnes BJ. IRF5 is a novel regulator of CXCL13 expression in breast cancer that regulates CXCR5(+) B- and T-cell trafficking to tumor-conditioned media. Immunology and Cell Biology. 93: 486-99. PMID 25533286 DOI: 10.1038/Icb.2014.110 |
0.52 |
|
| 2014 |
Volk-Draper L, Hall K, Griggs C, Rajput S, Kohio P, DeNardo D, Ran S. Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. Cancer Research. 74: 5421-34. PMID 25274031 DOI: 10.1158/0008-5472.Can-14-0067 |
0.736 |
|
| 2014 |
Flister MJ, Endres BT, Rudemiller N, Sarkis AB, Santarriaga S, Roy I, Lemke A, Geurts AM, Moreno C, Ran S, Tsaih SW, De Pons J, Carlson DF, Tan W, Fahrenkrug SC, et al. CXM: a new tool for mapping breast cancer risk in the tumor microenvironment. Cancer Research. 74: 6419-29. PMID 25172839 DOI: 10.1158/0008-5472.Can-13-3212 |
0.717 |
|
| 2014 |
Mehner C, Hockla A, Miller E, Ran S, Radisky DC, Radisky ES. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget. 5: 2736-49. PMID 24811362 DOI: 10.18632/Oncotarget.1932 |
0.496 |
|
| 2014 |
Rajput S, Volk-Draper L, Hall K, Ran S. Abstract 771: TLR4 activation by paclitaxel promotes breast cancer recurrence and metastasis Cancer Research. 74: 771-771. DOI: 10.1158/1538-7445.Am2014-771 |
0.733 |
|
| 2014 |
Hall K, Volk-Draper L, Rajput S, DeNardo D, Ran S. Abstract 12: Tumor macrophages in clinical breast cancers transdifferentiate into lymphatic-like cells and structurally contribute to lymphatic vasculature Cancer Research. 74: 12-12. DOI: 10.1158/1538-7445.Am2014-12 |
0.726 |
|
| 2013 |
Engelmann D, Mayoli-Nüssle D, Mayrhofer C, Fürst K, Alla V, Stoll A, Spitschak A, Abshagen K, Vollmar B, Ran S, Pützer BM. E2F1 promotes angiogenesis through the VEGF-C/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B. Journal of Molecular Cell Biology. 5: 391-403. PMID 24014887 DOI: 10.1093/Jmcb/Mjt035 |
0.526 |
|
| 2013 |
Rajput S, Volk-Draper LD, Ran S. TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Molecular Cancer Therapeutics. 12: 1676-87. PMID 23720768 DOI: 10.1158/1535-7163.Mct-12-1019 |
0.704 |
|
| 2012 |
Volk-Draper LD, Rajput S, Hall KL, Wilber A, Ran S. Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy. Neoplasia (New York, N.Y.). 14: 926-42. PMID 23097627 DOI: 10.1593/Neo.12956 |
0.644 |
|
| 2012 |
Ran S, Montgomery KE. Macrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors. Cancers. 4: 618-57. PMID 22946011 DOI: 10.3390/Cancers4030618 |
0.571 |
|
| 2012 |
Hall KL, Volk-Draper LD, Flister MJ, Ran S. New model of macrophage acquisition of the lymphatic endothelial phenotype. Plos One. 7: e31794. PMID 22396739 DOI: 10.1371/Journal.Pone.0031794 |
0.674 |
|
| 2012 |
Yoshioka S, King ML, Ran S, Okuda H, MacLean JA, McAsey ME, Sugino N, Brard L, Watabe K, Hayashi K. WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway. Molecular Cancer Research : McR. 10: 469-82. PMID 22232518 DOI: 10.1158/1541-7786.Mcr-11-0177 |
0.485 |
|
| 2012 |
Volk-Draper L, Hall K, Flister M, Ran S. Abstract 400: A new model for macrophage transdifferentiation into lymphatic endothelial cell progenitors Cancer Research. 72: 400-400. DOI: 10.1158/1538-7445.Am2012-400 |
0.702 |
|
| 2011 |
Mohamedali KA, Ran S, Gomez-Manzano C, Ramdas L, Xu J, Kim S, Cheung LH, Hittelman WN, Zhang W, Waltenberger J, Thorpe PE, Rosenblum MG. Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2. Bmc Cancer. 11: 358. PMID 21849059 DOI: 10.1186/1471-2407-11-358 |
0.436 |
|
| 2011 |
Volk LD, Flister MJ, Chihade D, Desai N, Trieu V, Ran S. Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases. Neoplasia (New York, N.Y.). 13: 327-38. PMID 21472137 DOI: 10.1593/Neo.101490 |
0.752 |
|
| 2011 |
Flister MJ, Volk LD, Ran S. Characterization of Prox1 and VEGFR-3 expression and lymphatic phenotype in normal organs of mice lacking p50 subunit of NF-κB. Microcirculation (New York, N.Y. : 1994). 18: 85-101. PMID 21166921 DOI: 10.1111/J.1549-8719.2010.00057.X |
0.638 |
|
| 2011 |
Korte M, Rajput S, Ran S. Abstract 5585: Generation of novel cell lines for analyzing the role of TLR4 in breast cancer Cancer Research. 71: 5585-5585. DOI: 10.1158/1538-7445.Am2011-5585 |
0.631 |
|
| 2011 |
Hayashi K, Yoshioka S, Ran S, Maclean JA. Abstract 3058: WNT7A regulates ovarian tumorigenesis through the canonical WNT signaling pathway Cancer Research. 71: 3058-3058. DOI: 10.1158/1538-7445.Am2011-3058 |
0.432 |
|
| 2011 |
Rajput S, Boral D, Ran S. Abstract 1700: TLR4 as a novel determinant of paclitaxel response in metastatic breast cancer Cancer Research. 71: 1700-1700. DOI: 10.1158/1538-7445.Am2011-1700 |
0.693 |
|
| 2011 |
King ML, Yoshioka S, Ran S, Sugino N, MacLean JA, Hayashi K. WNT7A Regulates Tumor Growth and Development Through the WNT/CTNNB1 Pathway in Ovarian Cancer. Biology of Reproduction. 85: 3-3. DOI: 10.1093/Biolreprod/85.S1.3 |
0.447 |
|
| 2010 |
Hall K, Ran S. Regulation of tumor angiogenesis by the local environment. Frontiers in Bioscience (Landmark Edition). 15: 195-212. PMID 20036815 DOI: 10.2741/3615 |
0.536 |
|
| 2010 |
Ran S, Volk L, Hall K, Flister MJ. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology : the Official Journal of the International Society For Pathophysiology / Isp. 17: 229-51. PMID 20036110 DOI: 10.1016/J.Pathophys.2009.11.003 |
0.75 |
|
| 2010 |
Flister MJ, Wilber A, Hall KL, Iwata C, Miyazono K, Nisato RE, Pepper MS, Zawieja DC, Ran S. Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1. Blood. 115: 418-29. PMID 19901262 DOI: 10.1182/Blood-2008-12-196840 |
0.668 |
|
| 2010 |
Cheng JM, Volk L, Janaki DK, Vyakaranam S, Ran S, Rao KA. Tumor suppressor function of Rab25 in triple-negative breast cancer. International Journal of Cancer. Journal International Du Cancer. 126: 2799-812. PMID 19795443 DOI: 10.1002/Ijc.24900 |
0.558 |
|
| 2010 |
Dhiwakar M, Malone JP, Kay PA, Robbins KT, Ran S. Use of angiopoietin-1 expression in squamous cell carcinoma of the head and neck to predict disease-free survival. Journal of Clinical Oncology. 28: 5542-5542. DOI: 10.1200/Jco.2010.28.15_Suppl.5542 |
0.42 |
|
| 2010 |
Desai N, Piacente M, Liu X, D'Cruz O, Hwang L, Lin X, Ran S, Markovic S, Motamed K, Trieu VN. Effect of plasma SPARC on outcome in cancer models. Journal of Clinical Oncology. 28: 10600-10600. DOI: 10.1200/Jco.2010.28.15_Suppl.10600 |
0.44 |
|
| 2010 |
Hayashi K, Yoshioka S, Ran S, McAsey M, Maclean JA. Abstract 3904: Potential role of WNT7A in ovarian cancer Cancer Research. 70: 3904-3904. DOI: 10.1158/1538-7445.Am10-3904 |
0.421 |
|
| 2010 |
Volk L, Boral D, Wilber A, Desai N, Trieu V, Ran S. Abstract 3852: Combination treatment ofnab-paclitaxel and bevacizumab in a new model of triple-negative breast cancer Cancer Research. 70: 3852-3852. DOI: 10.1158/1538-7445.Am10-3852 |
0.52 |
|
| 2010 |
Flister MJ, Hall KL, Wilber A, Ran S. Abstract 3442: Inflammatory mediators activate lymphatic endothelial cells (LECs) through elevation of NF-κB, Prox1, and VEGFR-3 Cancer Research. 70: 3442-3442. DOI: 10.1158/1538-7445.Am10-3442 |
0.691 |
|
| 2010 |
Volk L, Wilber A, Desai N, Trieu V, Ran S. Abstract 3279: Nab-paclitaxel and bevacizumab treatment in new models of inflammatory breast cancer, SUM149-RR and SUM149-GL Cancer Research. 70: 3279-3279. DOI: 10.1158/1538-7445.Am10-3279 |
0.543 |
|
| 2010 |
Hall K, Flister M, Volk L, Curry S, Wilber A, Ran S. Abstract 2354: Angiopoietin-2 role in breast cancer metastasis Cancer Research. 70: 2354-2354. DOI: 10.1158/1538-7445.Am10-2354 |
0.749 |
|
| 2010 |
Ran S, Trieu V, Volk L, Wilber A, Desai N. Abstract P1-03-11: Combination ofnab-Paclitaxel and Bevacizumab Inhibited Tumor Growth and Metastasis of a New Triple Negative Breast Cancer Model Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P1-03-11 |
0.507 |
|
| 2010 |
Volk L, Wilber A, Trieu V, Desai N, Ran S. Abstract P1-03-09: Combination ofnab-Paclitaxel and Bevacizumab Inhibited Tumor Growth and Metastasis of New Inflammatory Breast Cancer Models Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P1-03-09 |
0.551 |
|
| 2009 |
Ronen O, Malone JP, Kay P, Bivens C, Hall K, Paruchuri LP, Mo YY, Robbins KT, Ran S. Expression of a novel marker, Ubc9, in squamous cell carcinoma of the head and neck. Head & Neck. 31: 845-55. PMID 19309722 DOI: 10.1002/Hed.21048 |
0.446 |
|
| 2009 |
Desai N, Ran S, Volk L, Stutzman A, D'Cruz O, Trieu V. Antitumor activity, and antiangiogenic activity of nanoparticle albumin-boundnab-rapamycin in combination withnab-paclitaxel. Cancer Research. 69: 3125. DOI: 10.1158/0008-5472.Sabcs-3125 |
0.407 |
|
| 2009 |
Volk L, Stutzman A, Flister M, Hall K, Chihade D, Desai N, Trieu V, Ran S. Mechanisms ofnab-paclitaxel and bevacizumab cooperation in inhibition of breast tumor growth and metastasis. Cancer Research. 69: 1032. DOI: 10.1158/0008-5472.Sabcs-1032 |
0.733 |
|
| 2009 |
Hayashi K, Ran S, McAsey ME, MacLean JA. Role of WNT7A in Ovarian Cancer Metastasis. Biology of Reproduction. 81: 518-518. DOI: 10.1093/Biolreprod/81.S1.518 |
0.342 |
|
| 2008 |
Castro-Rivera E, Ran S, Brekken RA, Minna JD. Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells. Cancer Research. 68: 8295-303. PMID 18922901 DOI: 10.1158/0008-5472.Can-07-6601 |
0.519 |
|
| 2008 |
Volk LD, Flister MJ, Bivens CM, Stutzman A, Desai N, Trieu V, Ran S. Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia (New York, N.Y.). 10: 613-23. PMID 18516298 DOI: 10.1593/Neo.08302 |
0.739 |
|
| 2008 |
Ran S, Volk L, Bivens C, Trieu V, Desai N. Combination of nab®-paclitaxel and bevacizumab eradicates large orthotopic breast tumors and metastasis to lymph nodes and lungs European Journal of Cancer Supplements. 6: 220. DOI: 10.1016/S1359-6349(08)70893-0 |
0.305 |
|
| 2008 |
Ronen O, Malone JP, Ran S. R421 – Ubc9: A Novel Marker of Lymph Nodes Metastases in SCCHN: Otolaryngology-Head and Neck Surgery. 139: 184. DOI: 10.1016/J.Otohns.2008.05.575 |
0.348 |
|
| 2007 |
Whitehurst B, Flister MJ, Bagaitkar J, Volk L, Bivens CM, Pickett B, Castro-Rivera E, Brekken RA, Gerard RD, Ran S. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. International Journal of Cancer. Journal International Du Cancer. 121: 2181-91. PMID 17597103 DOI: 10.1002/Ijc.22937 |
0.737 |
|
| 2007 |
Trieu V, Ran S, Bivens C, Desai N. Chemoprotection by VEGF: Rationale for combination nab-paclitaxel and bevacizumab Journal of Clinical Oncology. 25: 1064-1064. DOI: 10.1200/jco.2007.25.18_suppl.1064 |
0.497 |
|
| 2006 |
Whitehurst B, Eversgerd C, Flister M, Bivens CM, Pickett B, Zawieja DC, Ran S. Molecular profile and proliferative responses of rat lymphatic endothelial cells in culture. Lymphatic Research and Biology. 4: 119-42. PMID 17034293 DOI: 10.1089/Lrb.2006.4.119 |
0.673 |
|
| 2006 |
Ran S, Bivens C, Trieu V, Desai N. 110 POSTER Synergistic effect of nab-paclitaxel and anti-VEGF-A antibody (bevacizumab) against the metastasis of breast tumor xenografts European Journal of Cancer Supplements. 4: 37. DOI: 10.1016/S1359-6349(06)70116-1 |
0.404 |
|
| 2005 |
Ran S, Mohamedali KA, Luster TA, Thorpe PE, Rosenblum MG. The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. Neoplasia (New York, N.Y.). 7: 486-96. PMID 15967101 DOI: 10.1593/Neo.04631 |
0.516 |
|
| 2005 |
Ran S, He J, Huang X, Soares M, Scothorn D, Thorpe PE. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 1551-62. PMID 15746060 DOI: 10.1158/1078-0432.Ccr-04-1645 |
0.513 |
|
| 2004 |
Castro-Rivera E, Ran S, Thorpe P, Minna JD. Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proceedings of the National Academy of Sciences of the United States of America. 101: 11432-7. PMID 15273288 DOI: 10.1073/Pnas.0403969101 |
0.571 |
|
| 2004 |
Bandyopadhyay S, Pai SK, Hirota S, Hosobe S, Takano Y, Saito K, Piquemal D, Commes T, Watabe M, Gross SC, Wang Y, Ran S, Watabe K. Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene. 23: 5675-81. PMID 15184886 DOI: 10.1038/Sj.Onc.1207734 |
0.469 |
|
| 2003 |
Mason RP, Constantinescu A, Ran S, Thorpe PE. Oxygenation in a human tumor xenograft: manipulation through respiratory challenge and antibody-directed infarction. Advances in Experimental Medicine and Biology. 530: 197-204. PMID 14562717 DOI: 10.1007/978-1-4615-0075-9_19 |
0.434 |
|
| 2003 |
Zhao D, Ran S, Constantinescu A, Hahn EW, Mason RP. Tumor oxygen dynamics: correlation of in vivo MRI with histological findings. Neoplasia (New York, N.Y.). 5: 308-18. PMID 14511402 DOI: 10.1016/S1476-5586(03)80024-6 |
0.457 |
|
| 2003 |
Ran S, Huang X, Downes A, Thorpe PE. Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy. Neoplasia (New York, N.Y.). 5: 297-307. PMID 14511401 DOI: 10.1016/S1476-5586(03)80023-4 |
0.488 |
|
| 2003 |
Castro-Rivera E, Ran S, Thrope P, Minna J. O-302 Semaphorin-3B and VEGF165 exert antagonistic effects on the survival and apoptosis of non-small lung cancer cells Lung Cancer. 41: S88. DOI: 10.1016/S0169-5002(03)91960-X |
0.339 |
|
| 2002 |
Mason RP, Ran S, Thorpe PE. Quantitative assessment of tumor oxygen dynamics: molecular imaging for prognostic radiology. Journal of Cellular Biochemistry. Supplement. 39: 45-53. PMID 12552601 DOI: 10.1002/Jcb.10404 |
0.343 |
|
| 2002 |
Zhang W, Ran S, Sambade M, Huang X, Thorpe PE. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis. 5: 35-44. PMID 12549858 DOI: 10.1023/A:1021540120521 |
0.557 |
|
| 2002 |
Ran S, Thorpe PE. Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. International Journal of Radiation Oncology, Biology, Physics. 54: 1479-84. PMID 12459374 DOI: 10.1016/S0360-3016(02)03928-7 |
0.503 |
|
| 2002 |
Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Research. 62: 6132-40. PMID 12414638 |
0.401 |
|
| 2002 |
Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proceedings of the National Academy of Sciences of the United States of America. 99: 7866-71. PMID 12060733 DOI: 10.1073/Pnas.122157899 |
0.502 |
|
| 2000 |
Thorpe PE, Ran S. Tumor infarction by targeting tissue factor to tumor vasculature Cancer Journal. 6. PMID 10874493 |
0.325 |
|
| 1998 |
Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP. Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo Blood. 92: 4150-4166. DOI: 10.1182/Blood.V92.11.4150.423K45_4150_4166 |
0.473 |
|
| Show low-probability matches. |